Third, miR-1226-3p is lowly expressed in HCC cells, and it promotes the sensitivity of HCC cells to sorafenib by downregulating DUSP4 and affecting the JNK-Bcl-2 pathway (21). Here, BCL2 is linked to hepatocellular carcinoma.